Full Text View
Tabular View
Study Results
Related Studies
Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy
This study has been completed.
Study NCT00734929   Information provided by Duke University

First Received on August 13, 2008.   Last Updated on May 5, 2011   History of Changes
Results First Received: April 7, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Prevention
Condition: Postoperative Nausea and Vomiting
Interventions: Drug: Aprepitant + Dexamethasone
Drug: Ondansetron + Dexamethasone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The study took place at Duke University Medical Center from September 2007 to June 2009

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Aprepitant Aprepitant 40 mg preoperatively + dexamethasone 10 mg after induction of anesthesia
Ondansetron Ondansetron 4 mg within 30 minutes of the end of surgery + Dexamethasone 10 mg after induction of anesthesia

Participant Flow:   Overall Study
    Aprepitant     Ondansetron  
STARTED     52     55  
COMPLETED     51     53  
NOT COMPLETED     1     2  
prolonged postoperative ventilation                 1                 2  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Aprepitant Aprepitant 40 mg preoperatively + dexamethasone 10 mg after induction of anesthesia
Ondansetron Ondansetron 4 mg within 30 minutes of the end of surgery + Dexamethasone 10 mg after induction of anesthesia

Baseline Measures
    Aprepitant     Ondansetron     Total  
Number of Participants  
[units: participants]
  52     55     107  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     52     55     107  
>=65 years     0     0     0  
Age  
[units: years]
Mean ± Standard Deviation
  51  ± 13     48  ± 13     50  ± 13  
Gender  
[units: participants]
     
Female     30     28     58  
Male     22     27     49  
Region of Enrollment  
[units: participants]
     
United States     52     55     107  



  Outcome Measures

1.  Primary:   Cumulative Incidence of Emesis   [ Time Frame: 48 h ]

2.  Secondary:   Incidence of Nausea   [ Time Frame: PACU ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

3.  Secondary:   Incidence of Nausea   [ Time Frame: 24 h ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

4.  Secondary:   Incidence if Nausea   [ Time Frame: 48 h ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

5.  Secondary:   Incidence of Vomiting   [ Time Frame: PACU ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

6.  Secondary:   Incidence of Vomiting   [ Time Frame: 24 h ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

7.  Secondary:   Use of Rescue Antiemetics   [ Time Frame: PACU ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

8.  Secondary:   Use of Rescue Antiemetics   [ Time Frame: 24 h ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

9.  Secondary:   Use of Rescue Antiemetics   [ Time Frame: 48 h ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

10.  Secondary:   Complete Response Rate   [ Time Frame: PACU, 24 h, 48 h ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

11.  Secondary:   Nausea Scores   [ Time Frame: PACU, 24 h, 48 h ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

12.  Secondary:   Number of Vomiting Episodes   [ Time Frame: 48 h ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

13.  Secondary:   Time to First Vomiting   [ Time Frame: 48 h ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

14.  Secondary:   Patient Satisfaction   [ Time Frame: 48 h ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Dr. Ashraf Habib
Organization: Duke University Medical Center
phone: 9196686265
e-mail: habib001@mc.duke.edu


Publications of Results:

Responsible Party: Ashraf Habib, Duke University Medical Center
ClinicalTrials.gov Identifier: NCT00734929     History of Changes
Other Study ID Numbers: 1404
Study First Received: August 13, 2008
Results First Received: April 7, 2011
Last Updated: May 5, 2011
Health Authority: United States: Institutional Review Board